← All trials
NCT05819775
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 24, 2023
- Primary completion
- Jun 11, 2026
- Completion date
- Jun 11, 2026
- First posted
- Apr 19, 2023
- Last posted
- Nov 30, 2023
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- CSL BehringLead sponsor
- CSL BehringStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.